Skip to content
University of Colorado Anschutz Medical Campus CU Anschutz
  • Webmail
  • UCD Access
  • Canvas
  • Quick Links
 

Tools & Resources

  • Events Calendar
  • Newsroom
  • Strauss Health Sciences Library
  • Department A-Z Directory
  • Campus Directory
  • Leadership
  • Faculty & Staff Resources
  • Supporter & Alumni Resources
  • Student Resources
  • Campus Map
  • University Policies
  • Give Now

CU Campuses

  • CU Anschutz Medical Campus
  • CU Boulder
  • CU Colorado Springs
  • CU Denver
  • CU System
  • CU Online

CU Anschutz Medical Campus

  • School of Dental Medicine
  • Graduate School
  • School of Medicine
  • College of Nursing
  • Skaggs School of Pharmacy and Pharmaceutical Sciences
  • Colorado School of Public Health

Division of Medical Oncology

School of Medicine

  • Home
  • Leadership
    • Division Head | Wells Messersmith, MD, FACP
    • Deputy Division Head | Virginia Borges, MD, MMSc
  • Research
  • Cancer Care
    • CARE Clinic
    • Clinical Trials
    • Find a Provider
    • Satellite Locations
  • Education
  • Giving
  • Newsroom
  • Division Resources
  • Division Directory
    • Clinical & Research Faculty
    • Research Services Personnel
    • Administrative Staff
University Quick Links
  • Home
  • Newsroom

Medical Oncology Newsroom

New Clinical Trial to Treat Metastatic Colorectal Cancer

Sep 28, 2022

Assistant Professor, Robert Lentz, MD, is spearheading a new phase 2 clinical trial for patients with metastatic colon cancer for whom chemotherapy and biologic therapy are no longer effective treatment options.  Colorectal cancer is the third most common and third most deadly cancer among both men and women in the United States but in Dr. Lentz's opinion, "we really need to identify a way to generate an anti-tumor immune response in order to improve the lives of patients with colorectal cancer who do not respond to already-approved immune therapy drugs."   

This clinical trial is centered around "a novel combination that attempts to achieve an effective immunotherapy treatment where it has not succeeded in the past,” says Dr. Lentz.  Patients enrolled across five sites receiving treatment once a week should expect to see a response after at least nine weeks, ideally, tumor shrinkage or stability. The trial also includes a two-year overall survival follow-up to determine the longer-term effectiveness of the medication. Dr. Lentz along with his mentor, Wells Messersmith, MD, FACP, hope to have the study fully enrolled by the end of 2023.

Dr. Lentz says working on this study has been a great opportunity for him because he’s been able to track its development all the way from an early concept to the point where the first patient has actually received treatment.

“Over the next few months, the chance that some patients will respond to this is very gratifying,” he says. “It’s been a great educational experience not only in terms of scientific concepts and clinical and translational research, but also the nuts and bolts of developing a clinical trial. I think that all of those skills will set me up for success in order to lead future trials down the road.”

Learn More


 YOU MAY ALSO LIKE

CU ANSCHUTZ NEWS

CU CANCER CENTER NEWS

DIVISION OF HEMATOLOGY

UCHEALTH TODAY

Medical Oncology (SOM)

CU Anschutz

Research I South

12801 East 17th Avenue

8122

Aurora, CO 80045


720-848-0300

Facebook Twitter
School
  • School of Medicine Home
  • Find a Doctor
  • Find a Researcher
  • Departments
  • Contact Us
  • Donate
  • School Profiles
General
  • Affiliate/Partner Hospitals
  • CU Medicine
  • A-Z Index
  • Directory
  • Map and Parking
  • Webmail
Students
  • Apply Now
  • Alumni
  • Canvas
  • Health Science Library
  • Student Life
  • Colorado Springs Branch
  • Contact Us
  • Website Feedback
  • CU System
  • Privacy Policy
  • Terms of Use
  • Accessibility
  • Accreditation
  • Employment
  • Give Now
 

© 2022 The Regents of the University of Colorado, a body corporate. All rights reserved.

Accredited by the Higher Learning Commission. All trademarks are registered property of the University. Used by permission only.

CMS Login

Webmail

UCD Access

Canvas

Opens in a new window Opens document in a new window